Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Dkll303 May. 15 at 5:24 PM

$CADL fidelity will sell this on a heart beat , they did at $CHRS , they did at $AGIO …they aren’t Blackrock or wellington , ya , where is wellington mgmt , ???( they know better , tAK is no ceo material ) You are clearly , without deep pocket friends , hahah @telomerase

0 · Reply

Jstocks33 May. 15 at 5:18 PM

$CHRS people always sell the news. The days looking up to earnings report are usually when prices rise so that people can get skin in the game in case it potentially skyrocket. If it doesn’t have amazing results, they immediately sell. It’s normal… The recent earnings report which was really OK, just not amazing, it has been pretty stable for overall stock price. I anticipated to continue to trade sideways between $1.50 and $1.70 until May 27 when we have the annual meeting of stockholders. Clinical data is revealed in August.

1 · Reply

cdlawton07 May. 15 at 5:02 PM

$CHRS gotta love 25% price swings on no news.

1 · Reply

WebRub May. 15 at 2:26 PM

$CHRS just following the XBI, we have seen this before.

0 · Reply

BigDaddyCapital May. 15 at 2:20 PM

$CHRS more major selling. These are not retail these are funds that know the data coming is piss poor

2 · Reply

simonig1 May. 15 at 1:56 PM

$CHRS Coherus Biosciences Signals Confident Oncology Earnings Outlook Link: https://www.theglobeandmail.com/investing/markets/stocks/CHRS-Q/pressreleases/1918337/coherus-biosciences-signals-confident-oncology-earnings-outlook/

1 · Reply

MA80SA May. 15 at 1:31 PM

$CHRS

0 · Reply

Samishere May. 15 at 12:40 PM

$CHRS By “ range-bound “ do you mean down 15-20% on a weekly basis ? Pretty Ff’d up range. 🤪🤣

0 · Reply

TomMac64 May. 15 at 12:18 PM

$CHRS This is not a lie it needs to be fixed !

1 · Reply

Jack_Nicholson_Truth May. 15 at 11:34 AM

$CHRS every employee at chrs wants chrs at $1.69 on may 27. 10m rsu will be repriced from average $15 to $1.69 ish. BIGDADDY AND SAMI ARE THE SAME LYING ACCOUNTS BOTS WHO POST SELL EVERYDAY SINCE $0.70. WE CHOP INTO THE VOTE!

1 · Reply

Coherus Oncology reports Q1 EPS (28c), consensus (26c)

May 11, 2026, 5:00 PM EDT - 3 days ago

Coherus Oncology Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 days ago

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T12:37:08.000Z - 4 days ago

Guggenheim starts Coherus with Buy on anti-tumor potential

2026-05-11T10:36:08.000Z - 4 days ago

Coherus Oncology initiated with a Buy at Guggenheim

May 4, 2026, 9:30 AM EDT - 11 days ago

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 10, 2026, 2:50 PM EDT - 2 months ago

Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026

2026-03-09T20:40:57.000Z - 2 months ago

Coherus Oncology reports Q4 EPS (34c), consensus (31c)

Mar 9, 2026, 4:30 PM EDT - 2 months ago

Coherus Oncology Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:15 PM EDT - 2 months ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

2026-03-09T12:06:26.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 09, 2026

CASY DDD FCEL HPE LFMD WTI YEXT

Mar 4, 2026, 11:50 AM EST - 2 months ago

Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:30 AM EST - 2 months ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 2 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 3 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

2026-02-13T11:50:56.000Z - 3 months ago

Coherus Oncology 28.6M share Spot Secondary priced at $1.75

Feb 12, 2026, 9:18 PM EST - 3 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

2026-02-12T21:12:06.000Z - 3 months ago

Coherus Oncology announces common stock offering, no amount given

2026-01-22T21:16:58.000Z - 4 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

2026-01-22T21:11:03.000Z - 4 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer

Jan 13, 2026, 1:30 PM EST - 4 months ago

Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:30 AM EST - 4 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:51:47.000Z - 4 months ago

Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug

Jan 5, 2026, 9:30 AM EST - 4 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 17, 2025, 1:30 PM EST - 5 months ago

Coherus Oncology Transcript: Biotech Discovery Series

2025-12-08T13:45:59.000Z - 5 months ago

Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial

Dec 8, 2025, 8:30 AM EST - 5 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 18, 2025, 5:30 AM EST - 6 months ago

Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025

2025-11-13T22:35:29.000Z - 6 months ago

Coherus Oncology files $150M mixed securities shelf

Nov 10, 2025, 1:15 PM EST - 6 months ago

Coherus Oncology Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 6 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 5:00 PM EST - 6 months ago

Coherus Oncology Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:14 PM EST - 6 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 6 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 7 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 9:05 AM EDT - 8 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 1:00 PM EDT - 8 months ago

Coherus Oncology Transcript: UBS Virtual Oncology Day

Sep 10, 2025, 11:00 AM EDT - 8 months ago

Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:25 PM EDT - 8 months ago

Coherus Oncology Transcript: Baird Global Healthcare Conference 2025

2025-09-04T11:35:24.000Z - 9 months ago

Coherus Biosciences upgraded to Buy from Neutral at Roth Capital

2025-09-04T11:35:13.000Z - 9 months ago

Coherus Biosciences upgraded to Buy from Hold at Maxim

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Coherus Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:41 PM EDT - 10 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 10 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2025

2025-05-30T12:11:11.000Z - 1 year ago

Coherus Biosciences completes transformation to Coherus Oncology

May 27, 2025, 3:00 PM EDT - 1 year ago

Coherus Oncology Transcript: 6th Annual Oncology Innovation Summit

2025-05-27T12:40:21.000Z - 1 year ago

Coherus Biosciences announces clinical collaboration with STORM Therapeutics

May 20, 2025, 12:00 PM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q1 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 9:00 AM EDT - 1 year ago

Coherus Oncology Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Transcript: KOL Event

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q4 2024

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 11:50 AM EST - 1 year ago

Coherus Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Transcript: at 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 3, 2024, 3:15 PM EST - 1 year ago

Coherus Oncology Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Coherus Oncology Transcript: Status Update

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q2 2024

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 2 years ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Coherus Oncology Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 12:00 PM EDT - 2 years ago

Coherus Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 5, 2024, 8:00 AM EST - 2 years ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Jan 22, 2024, 8:30 AM EST - 2 years ago

Coherus Oncology Transcript: Investor Update

Jan 22, 2024, 1:15 AM EST - 2 years ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 18, 2024, 4:05 PM EST - 2 years ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Jan 10, 2024, 12:45 PM EST - 2 years ago

Coherus Oncology Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 4, 2024, 8:00 AM EST - 2 years ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

INO

Dkll303 May. 15 at 5:24 PM

0 · Reply

Jstocks33 May. 15 at 5:18 PM

1 · Reply

cdlawton07 May. 15 at 5:02 PM

$CHRS gotta love 25% price swings on no news.

1 · Reply

WebRub May. 15 at 2:26 PM

$CHRS just following the XBI, we have seen this before.

0 · Reply

BigDaddyCapital May. 15 at 2:20 PM

$CHRS more major selling. These are not retail these are funds that know the data coming is piss poor

2 · Reply

simonig1 May. 15 at 1:56 PM

1 · Reply

MA80SA May. 15 at 1:31 PM

$CHRS

0 · Reply

Samishere May. 15 at 12:40 PM

$CHRS By “ range-bound “ do you mean down 15-20% on a weekly basis ? Pretty Ff’d up range. 🤪🤣

0 · Reply

TomMac64 May. 15 at 12:18 PM

$CHRS This is not a lie it needs to be fixed !

1 · Reply

Jack_Nicholson_Truth May. 15 at 11:34 AM

1 · Reply

Jack_Nicholson_Truth May. 14 at 9:08 PM

$CHRS chop chop into Denny repricing the shares. Shorts know they better cover once the Denny has 4m rsu shares all repriced to the price on may 27 2026. He will have about 4-5m shares at 1.67-1.80 and will get a massive 50-100m bonus I bet in a buyout. Also short volume has been 63%+ for three days meaning this algo trading. Our volume is $3M-4M a day. We need much more

0 · Reply

BigDaddyCapital May. 14 at 7:14 PM

$CHRS keep in mind this has dropped almost 50 cents in 3 days. Do not fall for this shitco… can’t afford anything without another raise & they want dilute in shareholder meeting. Denny is a bad actor, plus we may be hitting bubble territory this is toast with no cash by EoY

3 · Reply

Samishere May. 14 at 5:03 PM

$CHRS Theres no data read outs coming. You’ve been bambozzald by the best con man in the Biotech game! No data = more dilution = .50 cents a share Denny has produced exactly NOTHING as CEO of this mess !

0 · Reply

PlutoAnalyses May. 14 at 4:37 PM

Explore the complexities of the CANCER INDUSTRY. 1. Discover why every major pharmaceutical giant is racing to claim a stake in this booming market. 2. Set to skyrocket to a staggering 700 billion dollars by 2034, making it the biggest market for biotech. 3. 85% of drugs using the FDA's accelerated approval pathway are for cancer. 4. Cancer drugs cost triple the price of standard medications, even in tightly regulated countries, and the reasons go far beyond survival rates. Join the conversation and read the full article for free right here: https://open.substack.com/pub/plutoanalyses/p/inside-the-cancer-industry-navigating?r=5e6tza&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true $XBI , $IBB , $VSTM , $CHRS , $CGON

0 · Reply

Grandgustav May. 14 at 3:39 PM

$CHRS I think we find out right after June 30 whether we get the first $37.5 milion earn-out, which is more than we lost last quarter. And I believe we'll hear about the second earn-out right after Sept. 30. That would add two quarters to our runway right there, and all five data readouts would be out.

2 · Reply

Thomas105 May. 14 at 2:12 PM

$CHRS Bears are fckd Upward trend continous

1 · Reply

BigDaddyCapital May. 14 at 1:34 PM

$CHRS bye bye waterfall event

1 · Reply

Jack_Nicholson_Truth May. 14 at 11:07 AM

$CHRS why so much volatility? Because 30m shares short.

0 · Reply

Jack_Nicholson_Truth May. 14 at 9:34 AM

$CHRS this scammer only posts bearish surf posts about chrs on down days. Same posts. Good luck to you bear scammer

1 · Reply

Yarrow May. 13 at 11:30 PM

$CHRS Yep, that was the Joke. Where didn't you see the humor in that?

0 · Reply

Jack_Nicholson_Truth May. 13 at 11:18 PM

$CHRS stop crying about surf from 2022! SURF WAS GOING OUT OF BUSINESS BY 2021. We saved you 3-4 years ago from complete loss.

1 · Reply

Yarrow May. 13 at 10:03 PM

$CHRS I'm going to sue SURF for getting me into this garbage.

1 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26